Archive

UEGW 2015: Low risk Barrett’s oesophagus: To leave or treat? An interview with Professor Prateek Sharma, University of Kansas Medical Center, USA. Conducted by Sanjay Tanday.

UEGW 2015: Management of IBD after anti-TNF failure. Professor Laurent Peyrin-Biroulet (Nancy, France) discusses his presentation on when to use anti-integrins or anti-TNFs and the iCARE programme sponsored by ECCO.

by Maria Dalby: Managing patients with active disease who fail to respond to anti-TNF therapy remains a key unmet need in IBD. Introducing a free paper session on… read more.

IBD: What's new in 2015: Professor Laurent Peyrin-Biroulet (Nancy, France), Professor Prateek Sharma (Kansas, USA), Professor Brian Feagan (London, Canada) and Professor David Wilson (Edinburgh, UK) discuss their highlights of UEGW 2015. Conducted by Sanjay Tanday.

by Sanjay Tanday: Advances in diagnostics and therapy means the prospects of living a normal active life free of symptoms and disability are better than ever for IBD… read more.

IBD: What’s new in 2015: Professor Laurent Peyrin-Biroulet (Nancy, France), Professor Prateek Sharma (Kansas, USA), Professor Brian Feagan (London, Canada) and Professor David Wilson (Edinburgh, UK) discuss their highlights of UEGW 2015. Conducted by Sanjay Tanday.

by Sanjay Tanday: Advances in diagnostics and therapy means the prospects of living a normal active life free of symptoms and disability are better than ever for IBD… read more.

UEGW 2015: Complications of Crohn's disease

by Maria Dalby: Accurate diagnosis and monitoring are key elements in the prevention of long-term complications of Crohn’s disease including stenosis, strictures and perforation. Rising Star award winner… read more.

UEGW 2015: Complications of Crohn’s disease

by Maria Dalby: Accurate diagnosis and monitoring are key elements in the prevention of long-term complications of Crohn’s disease including stenosis, strictures and perforation. Rising Star award winner… read more.

Remsima®, a biosimilar infliximab, shows efficacy and safety in “real world” analysis

by Bruce Sylvester – New “real world” data suggests that the efficacy of Remsima® (infliximab),  a biosimilar monoclonal antibody (mAb) anti-TNF-alpha agent approved by the European Commission, is… read more.